Stage III-IV or Recurrent Endometrial Cancer Clinical Trial
Official title:
A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Wright et al (Anticancer Res, 2000) reported the results of a retrospective study on 11
patients with advanced/recurrent endometrial cancers. All patients had multi-site disease
and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received
bevacizumab combination therapy which was well-tolerated. Two patients had partial
responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable
for response. The median progression-free interval was 5.4 months for the entire cohort and
8.7 months for those who achieved clinical benefit (PR or SD). The authors concluded that
Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients
with endometrial cancer.The rationale for combining anti-angiogenic agents, including
anti-VEGF antibodies, with cytotoxic chemotherapy stems from a number of preclinical studies
showing additive and synergistic anti-tumour activity in a number of solid tumour types. By
combining VEGF-targeting agents such as bevacizumab with conventional chemotherapies, it is
hoped that these agents will act synergistically, thereby enhancing their anti-tumour
efficacy and controlling disease progression.
The addition of bevacizumab to chemotherapy has been shown to improve PFS and/or OS in a
series of large, randomized Phase III clinical trials in a wide range of tumour types,
including mCRC, non-squamous NSCLC, metastatic BC (mBC) and mRCC.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment